Cargando…
Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection
OBJECTIVES: Treatment with pegylated interferon and ribavirin may prevent progression of liver disease among patients with chronic hepatitis C virus infection (HCV). Treatment initiation is based on published clinical eligibility criteria, patients’ willingness to undergo treatment and likelihood of...
Autores principales: | Livingston, Stephen E., Townshend-Bulson, Lisa J., Bruden, Dana L., McMahon, Brian J., Homan, Chriss E., Gove, James E., Deubner, Heike, Bruce, Michael G., Robinson, Renee F., Gretch, David R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Co-Action Publishing
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417585/ https://www.ncbi.nlm.nih.gov/pubmed/22564468 http://dx.doi.org/10.3402/ijch.v71i0.18445 |
Ejemplares similares
-
Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C
por: Livingston, Stephen E., et al.
Publicado: (2016) -
The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals
por: Townshend-Bulson, Lisa, et al.
Publicado: (2021) -
Autoimmune hepatitis and overlap syndrome among Alaska Native people: Prevalence, clinical characteristics, and remission
por: Johnston, Janet M., et al.
Publicado: (2023) -
Mortality among Alaska Native Adults with Confirmed Hepatitis C Virus Infection Compared with the General Population in Alaska, 1995–2016
por: Bressler, Sara S., et al.
Publicado: (2022) -
Hepatitis C in pregnant American Indian and Alaska Native women; 2003-2015
por: Nolen, Leisha D., et al.
Publicado: (2019)